ClinicalTrials.gg
CompletedNCT06318637Updated Sep 24, 2025

Evaluation of the Acceptability and Feasibility of a Bedtime Routine for Neonates

An interventional study of Baby Wash/Shampoo and Daily Activities in Newborn, sponsored by Johnson & Johnson Consumer Inc. (J&JCI). Completed at 1 site in United States. Open to participants aged 2 Weeks and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-24.

Sponsored by Johnson & Johnson Consumer Inc. (J&JCI) (formerly part of Johnson & Johnson) · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
2 Weeks and older
Sex
All
01

Study summary

The purpose of this study is to assess, via caregiver questionnaire, the acceptability and feasibility of implementing a bedtime routine for newborns.

02

Conditions studied

  • Newborn
03

In context

Lead sponsor

Johnson & Johnson Consumer Inc. (J&JCI) is the lead sponsor of 55 studies on the registry; none are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 10 (83%) have results posted.

First submitted after Johnson & Johnson Consumer Inc. (J&JCI) left Johnson & Johnson.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Weeks and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Infant:

  • Full term at birth (gestational age greater than or equal to [>=] 37 weeks)
  • A singleton birth. (Having other infants/children in the household will be allowed but only 1 child per household may be enrolled)
  • Breastfed, formula-fed, or combination

Caregiver:

  • Able to read, write, speak, and understand English
  • Must be the parent (biological or adoptive) and legal guardian of the infant participant who is willing and able to present proof of legal guardianship (example: birth certificate/hospital discharge paperwork along with valid ID of legal guardian, etc.)

Exclusion criteria

Exclusion Criteria:

Caregiver and infant:

  • Has known allergies or adverse reactions to common topical skincare products or the ingredients in the study materials
  • Has a history of or a concurrent health condition/situation which, in the opinion of the Principal Investigator (PI) or Study Physician, may put the individual at significant risk, confound the study results, or interfere significantly with the individual's participation in the study
  • Is simultaneously participating in any other clinical study or has participated in a clinical study since infant's birth
  • Is an employee/contractor or immediate family member of the PI, Study Site, or Sponsor
  • Presents with a skin condition that may influence the outcome of the study (specifically psoriasis, eczema, atopic dermatitis, or erythema)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
132 participants (actual)

Study arms

  • Active comparator
    Control Group

    Participants in the control group will follow their typical daily activities with their baby throughout the study, including their typical bathing, skincare, and sleep practices.

    Other: Daily Activities

  • Experimental
    Interventional Group (Wash/Shampoo and Lotion)

    Participants in the intervention group will use the provided wash/shampoo, and face and body lotion for their baby. At Baseline, participants caregivers in the intervention group will be provided with instructions for institution of a daily bedtime routine for their infant, which includes a massage with a moisturizing lotion.

    Other: Baby Wash/Shampoo · Other: Body Lotion

Interventions

  • OtherBaby Wash/Shampoo

    Marketed baby wash/shampoo to be used as needed.

  • OtherDaily Activities

    Participants to follow their typical daily activities with their baby.

  • OtherBody Lotion

    Marketed body lotion to be used as needed.

06

What researchers measure

Primary outcomes

  1. Bedtime Routine Acceptability and Feasibility to Caregivers

    Will collect agreement data to statements on bedtime routine acceptability using a 5-point Likert scale, ranging from strongly agree to strongly disagree. Will collect bedtime routine information, including wash up/bath, massage/apply lotion and quiet activity.

    Time frame: At Day 10

  2. Bedtime Routine Acceptability and Feasibility to Caregivers

    Will collect agreement data to statements on bedtime routine acceptability using a 5-point Likert scale, ranging from strongly agree to strongly disagree. Will collect bedtime routine information, including wash up/bath, massage/apply lotion and quiet activity.

    Time frame: At Day 17

  3. Bedtime Routine Acceptability and Feasibility to Caregivers

    Will collect agreement data to statements on bedtime routine acceptability using a 5-point Likert scale, ranging from strongly agree to strongly disagree. Will collect bedtime routine information, including wash up/bath, massage/apply lotion and quiet activity.

    Time frame: At 3 months

  4. Bedtime Routine Acceptability and Feasibility to Caregivers

    Will collect agreement data to statements on bedtime routine acceptability using a 5-point Likert scale, ranging from strongly agree to strongly disagree. Will collect bedtime routine information, including wash up/bath, massage/apply lotion and quiet activity.

    Time frame: At 6 months

07

Study locations

1 site
  • SGS North America, Inc.
    Richardson, Texas 75081, United States
08

References and documents

Individual participant data

Plan to share: Yes — Johnson \& Johnson Consumer Inc. has an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu.

Data sharing details ↗ · yoda.yale.edu

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2024 to primary completion in Aug 2025, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2024
First posted
Mar 19, 2024
StartActual
Apr 18, 2024
Primary completionActual
Aug 12, 2025
CompletionActual
Aug 12, 2025
Last update
Sep 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06318637
Responsible party
Sponsor
First posted
Mar 19, 2024
Start date
Apr 18, 2024
Primary completion
Aug 12, 2025
Completion
Aug 12, 2025
Last update
Sep 24, 2025

Study contacts

Nancy Rodgers, Ph.D.
principal investigator · SGS North America, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion